

Clinical Trial Transparency brings opportunity to improve public health



Prioritize transparency that drives better health outcomes

More Transparency does not mean better transparency.

What Transparency mechanisms bring value to patients? To Researchers? To better health outcomes for societies?



R&D Innovation needs to be protected and encouraged

Ensure EU remains a competitive place for clinical research to be preferred.



Diversity requires global clinical trials are accepted & not repeated

Regulators and the Public want efficiencies gained by not repeating trials locally, avoiding delays in medicine availability globally.



Clinical Research Integrity must be the priority

A clinical study must complete before results are published to protect the blinding.

Publication should be scientifically sound and unbiased.



Patient Trust is critical to clinical research & development

Patient data breaches will reduce trust.

Patient enrollment in clinical trials is a key contributor to how fast new medicines come to the market and improve global health.



Global Data Privacy Laws & Data Transfer laws must be enabled

Data disclosed anywhere impacts what can be disclosed elsewhere from a privacy perspective.

Data localization can inhibit transparency.

Transparency is important and regulations must create value for public health, not just tick boxes.